Elasmogen Ltd is a biopharmaceutical company which has developed a validated and IP-protected method of delivering drugs to specific sites in the human body.
This trademarked technique, called a soloMER platform, uses small, highly stable proteins (known as ‘domains’) that penetrate affected tissue to deliver drugs to their target. SoloMERs are derived from shark antibodies that have been adapted for safe use in the human body, which gives the Company a strong differentiation compared to similar products based on human antibodies.
The Company has a pipeline of ‘soloMER’ products in development for auto-immune mediated inflammatory diseases of the eye and inflammatory diseases of the bowel.
Delivering drugs using a soloMER platform will mean clinicians can be more certain the affected area has been targeted and that antibodies will remain active. It also offers a much less stressful method of treatment for patients.
Once pre-clinical and clinical trials are completed, Elasmogen Ltd will look to commercialise its ‘soloMER’ products by licencing its intellectual property to large pharmaceutical manufacturing companies.
|Life Sciences EIS
|Aim of funding
|HMRC Advanced Assurance received
|Envisaged investor exit
|In excess of 4x capital invested